Subscribe
Funding & M&A
5 min read

Chewy Is Buying Modern Animal — and Betting That Owning the Vet Is the Moat

Chewy has agreed to acquire Modern Animal, the tech-forward veterinary platform with 29 clinics and over 100,000 member families, adding $125 million in run-rate revenue and scaling Chewy Vet Care to 47 locations. The deal connects Chewy's commerce engine with Modern Animal's proprietary clinical tech and membership model, creating a closed-loop healthcare ecosystem that pressures every major veterinary consolidator.

Written by
The Underbite
Published on
April 8, 2026
Chewy Is Buying Modern Animal — and Betting That Owning the Vet Is the Moat

Chewy has agreed to acquire Modern Animal, the tech-forward veterinary platform with 29 clinics, 24/7 virtual care, and over 100,000 member families. The deal instantly scales Chewy Vet Care from 18 locations to 47 and adds more than $125 million in annualized run-rate revenue. This isn't a tuck-in. It's Chewy declaring that the future of pet retail runs through the exam room.

What Happened

Chewy announced a definitive agreement to acquire Modern Animal on April 8. Financial terms were not disclosed, but the deal adds over $125 million in annualized run-rate revenue and is expected to be EBITDA-dollar neutral in fiscal 2026 on a pro forma basis, with EBITDA-dollar contribution beginning in fiscal 2027.

Modern Animal, founded in 2018 by Steven Eidelman, operates 29 owned clinics across California, Texas, and Colorado. The company raised over $229 million in equity across four rounds, most recently a $46 million Series D in September 2025 led by Addition, Upfront Ventures, and True Ventures. It hit a $100 million revenue run rate in 2024 on 85% year-over-year growth. Its mature clinics generate EBITDA margins above 20% and more than double the industry-average revenue per location.

Chewy CEO Sumit Singh framed the acquisition as a platform play, calling Modern Animal's proprietary tech, membership model, and operating engine the foundation for a fully integrated pet health ecosystem using both owned and asset-light models. The company estimates 15–20% uplift in net sales per active customer across the combined veterinary network from cross-category purchasing, increased engagement, and member family retention.

Chewy's board simultaneously authorized a $500 million increase to its existing share repurchase program. Closing is expected in Q2 of fiscal 2026, subject to regulatory approval.

Why It Matters

This deal redraws the competitive map for veterinary services and pet commerce in ways that go well beyond clinic count.

1. Chewy is building a closed-loop healthcare ecosystem. The acquisition connects product commerce (food, pharmacy, supplements) with clinical care (exams, diagnostics, prescriptions) and virtual triage under one platform. That's the playbook Amazon tried with One Medical in human health, but Chewy has a structural advantage: pet owners already consolidate spending with a single retailer far more willingly than human patients do with a health system. With 20+ million active customers feeding into 47 vet locations, the cross-sell math gets very real very fast.

2. Modern Animal's tech stack is the real asset. Modern Animal built its own operating system from scratch — scheduling, records, internal communication, and AI-assisted clinical workflows. That's what makes the 15–20% net sales uplift estimate credible. Chewy isn't just buying clinics. It's buying the software to run clinics at higher throughput and margin than legacy practice management systems allow.

3. The membership model creates defensible recurring revenue. Modern Animal's 100,000+ member families pay for ongoing access to virtual and in-clinic care. For Chewy, layering membership on top of Autoship creates two interlocking retention loops — one for products, one for care. Competitors would need to build or buy both to replicate.

4. This pressures every corporate veterinary consolidator. Mars Veterinary Health (Banfield, VCA, BluePearl), NVA, and Pathway Vet Alliance have scaled through acquisition, but none have a direct-to-consumer commerce channel with Chewy's reach.

What to Watch

Integration speed matters more than clinic count. Watch for announcements about unified customer accounts, in-clinic Autoship enrollment, or pharmacy integration.

New clinic openings post-close. Any signal above 15 new locations per year would indicate Chewy is shifting from cautious experimentation to aggressive build-out.

Competitive response from Mars and NVA. Mars Veterinary Health operates roughly 3,000 clinics in the U.S. but has no comparable commerce platform.

Eidelman's role post-acquisition. Whether Modern Animal's founder stays will signal how much autonomy the brand retains.

Source: Chewy press release via Business Wire

See every deal in the Pet Industry M&A Tracker →

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles